Skip to main content

Table 1 Baseline characteristics

From: Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project

 

SCD individualsn = 481

No. (%) with clinical progression

70 (15%)

 Progression to MCI

49 (10%)

 Progression to AD dementia

10 (2%)

 Progression to non-AD dementia

11 (2%)

Age

62 ± 9

Gender, no. (%) females

211 (44%)

MMSE

28 ± 1.6

Follow-up duration

3 ± 2

Medial temporal lobe atrophy

0.4 ± 0.5

Global cortical atrophy

0.4 ± 0.6

Hippocampal volume (cm3)

7.2 ± 1

Normalized whole brain volume (cm3)

1453 ± 100

Amyloid β1–42

879 ± 260

Total Tau

298 ± 196

p-tau

49 ± 22

  1. Data are mean ± standard deviation, unless otherwise specified. MMSE mini-mental state examination, MRI magnetic resonance imaging, CSF cerebrospinal fluid